>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
合理用药干预对外科预防性使用质子泵抑制剂的影响
作者:李晓敏  余霞霞  邵华 
单位:东南大学附属中大医院 药学部, 江苏 南京 210009
关键词:质子泵抑制剂 应激性溃疡 干预 
分类号:R95
出版年·卷·期(页码):2019·38·第一期(43-46)
摘要:

目的:比较干预前后外科质子泵抑制剂(PPIs)的预防使用情况。方法:回顾性分析干预前(2016年4-6月)我院泌尿外科手术病例513例和同期干预后(2017年4-6月)手术病例623例,比较PPIs的预防使用情况。结果:干预前后PPIs预防使用率分别为80.51%和74.48%,两组比较有统计学差异(P<0.05);干预前后PPIs合理使用率分别为21.64%和28.41%,两组比较差异有统计学意义(P<0.01)。结论:对外科PPIs预防应用的药学干预措施可行且有效,促进了PPIs的合理使用。

Objective:To Compare the use of proton pump inhibitors before and after intervention in surgical department. Methods:This retrospective study assessed 513 patients before intervention(2016.4-6)and 623 patients after intervention(2017.4-6)in urology department to compare the usage of PPIs.Results:The treatment rate before and after intervention of PPIs was 80.51% and 74.48%, respectively.The differences were statistically significant(P<0.05).The reasonable use rate before and after intervention of PPIs was 21.64% and 28.41%, respectively.There were significantly statistical differences in comparison of data between the two groups(P<0.01).Conclusions:The pharmacy interventions for the preventire use of PPIs in Surgical Department are feasible and effective, thus the rational use of PPIs is promoted.

参考文献:

[1] 陈新谦,金有豫,汤光.新编药物学.第16版[M].人民卫生出版社,2007.
[2] 肖桂荣,吴欣雅,徐珽.应激性溃疡药物预防的国内外指南分析[J].华西医学,2014,29(12):2242-2245.
[3] 王树玲,方军,马丹,等.质子泵抑制剂在临床预防应激性溃疡中的作用[J].中华医学杂志,2016,96(26):2108-2110.
[4] 柏愚,李延青,任旭,等.应激性溃疡防治专家建议(2015版)[J].中华医学杂志,2015,95(20):1555-1557.
[5] 赵玉沛.应激性黏膜病变预防与治疗——中国普通外科专家共识(2015)[J].中国实用外科杂志,2015,35(7):728-730.
[6] 袁洪.湖南省质子泵抑制剂的临床应用指导原则(试行)[J].中南药学,2016,14(7):673-683.
[7] 郑松柏,姚健风.老年人质子泵抑制剂合理应用专家共识[J].中华老年医学杂志,2015,34(10):1-7.
[8] BATUWITAGE B T,KINGHAM J G,MORGAN N E,et al.Inappropriateprescribing of proton pumpinhibitors in primary care[J].Postgrad Med J,2007,83(975):66-68.
[9] RAMIREZ E,LEI SH,BOROBIA AM,et al.Overuse of PPI in patientsat admission,during treatment,and at discharge in a tertiary Spanishhospital[J].Curr Clin Pharmacol,2010,5(4):288-297.
[10] MASCLEE GM,STURKENBOOM MC,KUIPERS EJ,et al.A benefit-riskassessment of the use of proton pump inhibitors in the elderly[J].Drugs Aging,2014,31(4):263-282.
[11] FDA.Drug safety communication:possible increased risk of fracturesof the hip,wrist,and spine with the use of proton pump inhibitors[EB/OL].(2011-03-23)[2013-07-01].
[12] FDA.Proton pump inhibitors (PPI)-drug safety communication:clostridium difficile-associated diarrhea (CDAD) can be associatedwith stomach acid drugs[EB/OL].(2012-02-08)[2013-07-01].http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm290838.htm.
[13] ABRAHAM E.Acid suppression in a critical care environment:state ofthe art and beyond[J].Crit Care Med,2002,30(6 Suppl):S349-S350.
[14] BARDOU M,QUENOT J P,Barkun A.Stress-related mucosal diseasein the critically ill patient[J].Nat Rev Gastroenterol Hepatol,2015,12(2):98-107.
[15] CHOUNG R S,TALLEY N J.Epidemiology and clinical presentation ofstress-related peptic damage and chronic peptic ulcer[J].Curr Mol Med,2008,8(4):253-257.
[16] AHRENS D,CHENOT J F,BEHRENS G,et al.Appropriateness oftreatment recommendations for PPI in hospital discharge letters[J].Eur J Clin Pharmacol,2010,66(12):1265-1271.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 166795 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364